A new study has found that up to 20% of aggressive brain cancers are fueled by overactive mitochondria and new drugs in development may be able to starve the cancers.
Seizures are usually considered a side effect of brain cancer, but a new Columbia University study of mice suggests they may also fuel the further growth of brain tumors.
At Columbia, patients with brain cancer will be able to participate in a new type of clinical trial that promises to speed up the development of better drugs for glioblastoma.
Fewer than 1 in 10 patients with glioblastoma—the most common type of brain cancer—respond to immunotherapy; a new study reveals how to detect patients who may respond.
Though far from the most common form of cancer, brain cancers are uniquely difficult to treat. Columbia scientists are researching multiple new ways to attack the tumors.
The fusion of two adjacent genes can cause cancer by kicking mitochondria into overdrive and increasing the amount of fuel available for rampant cell growth.
The drug Gleevec is well known not only for its effectiveness against leukemia. A similar drug might be able to tame some brain cancers, new research from Columbia University Medical Center has shown.